51
|
Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, Chu Q, Mack PC, Cheng Y, Duan J, Fan Y, Han B, Hui Z, Liu A, Liu J, Lu Y, Ma Z, Shi M, Shu Y, Song Q, Song X, Song Y, Wang C, Wang X, Wang Z, Xu Y, Yao Y, Zhang L, Zhao M, Zhu B, Zhang J, Zhou C, Hirsch FR. Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395]. ESMO Open 2022; 7:100482. [PMID: 35461023 DOI: 10.1016/j.esmoop.2022.100482] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
52
|
Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Stefaniak V, Lin Y, Wang S, Zhang W, Sun L, Zhang Y. 4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
53
|
Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. 148P Pathological stage N1 limited-stage small-cell lung cancer patients can benefit from surgical resection. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
54
|
Qing Z, Gabrail N, Uprety D, Rotow J, Han B, Jänne P, Nagasaka M, Zheng M, Zhang Y, Yang G, Sun Y, Peng B, Wu YL. 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
55
|
Han B, Sun Z, Zhu J, Fu Z, Kong X, Barghi S. Bubble dynamics in
2‐D
gas‐solid fluidized bed with Geldart A or Geldart B particles by image processing method. CAN J CHEM ENG 2022. [DOI: 10.1002/cjce.24391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
56
|
Zhong R, Ling X, Cao S, Xu J, Zhang B, Zhang X, Wang H, Han B, Zhong H. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. ESMO Open 2021; 7:100334. [PMID: 34959168 PMCID: PMC8718955 DOI: 10.1016/j.esmoop.2021.100334] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 09/28/2021] [Accepted: 11/15/2021] [Indexed: 12/25/2022] Open
Abstract
Background Our prospective, open-label, single-arm phase II study investigated the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with standard carboplatin/pemetrexed in advanced non-squamous (nsq) non-small-cell lung cancer (NSCLC). Patients and methods Eligible patients had stage IV nsq NSCLC without oncogenic drivers and had not received prior systemic cancer therapy. Treatment consisted of carboplatin/pemetrexed for up to 6 cycles followed by 21 cycles of pemetrexed maintenance or until progression or intolerance. Non-progression patients after two cycles of chemotherapy started to receive DCVAC/LuCa subcutaneously (s.c.) on day 15 of cycle 3, and thereafter q3w (day 15 of chemotherapy cycles) for up to 15 doses. Dosing of DCVAC/LuCa s.c. varied among patients depending on the baseline number of leucocytes but remained constant for each single patient. Safety was assessed by adverse events (AEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). Efficacy was measured by overall survival (OS), progression-free survival (PFS), time to progression (TTP), and objective response rate (ORR). Results Sixty-one patients were enrolled. In the safety population (n = 60), eight patients (13.33%) had grade 3 or greater TRAEs, and six patients (10.0%) showed SAEs which were not related to leukapheresis or DC vaccination. Six grade 1 AEs were considered to be related to leukapheresis. No AESIs or DCVAC/LuCa-induced AEs were observed. The 2-year survival rate in the modified intention-to-treat population (n = 44) was 52.57%. Median OS was not reached. Median PFS was 8.0 months, median TTP was 10.2 months, and the ORR was 31.82%. Conclusion In treatment-naïve stage IV nsq NSCLC patients without oncogenic drivers, the combination of carboplatin/pemetrexed and DCVAC/LuCa was well tolerated and showed promising efficacy. Therefore, a study to prove our immunotherapeutic concept in a randomized phase III trial is planned. We investigated the safety and efficacy of DCVAC/LuCa combined with standard carboplatin/pemetrexed in nsq NSCLC. The combination therapy showed a favorable tolerability profile in a selected Chinese population. The 2-year survival rate in the modified intention-to-treat population (n = 44) was 52.57%.
Collapse
|
57
|
Ding HT, Liu YZ, Hai Y, Guan L, Pan AX, Zhang XN, Han B, Li Y. [Clinical application of sacral alar screw fixation in surgical treatment of lumbosacral degenerative disease]. ZHONGHUA YI XUE ZA ZHI 2021; 101:3718-3723. [PMID: 34856699 DOI: 10.3760/cma.j.cn112137-20210422-00966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To verify the safety and feasibility of sacral alar screw fixation and fusion surgery in lumbosacral area. Methods: The clinical and radiological data of patients receiving L5/S1 single-level cortical bone trajectory screw combined with sacral alar screw decompression fixation and fusion in Beijing Chaoyang Hospital due to lumbar spinal stenosis from January 2019 to January 2020 were retrospectively analyzed. The clinical data included operation duration, intraoperative blood loss, postoperative drainage, pain and function scores during follow-up. The radiological data included preoperative and postoperative follow-up X-rays and three-dimensional reconstruction of lumbar spine CT. The fusion status and complication of internal fixation, such as screw loosening and fixation failure were evaluated by the radiological examination. Results: According to the inclusion and exclusion criteria, a total of 16 patients (7 males and 9 females) were included, with an average age of (69.6±5.2) years. The patients were followed-up for (16.2±1.7) months. The average operation duration was (144±21) min, the intraoperative blood loss was (103±20) ml, and the postoperative drainage was (80±34) ml. The patient's low back pain visual analogue scale (VAS) score was 6.8±1.0 before surgery, and it was improved to 0.9±0.7 at the last follow-up; leg pain VAS score was 6.1±0.9 before the operation and it improved to 0.9±0.7 at the last follow-up; Oswestry disability index (ODI) function score was 66.2%±8.0% before the surgery and it decreased to 26.6%±7.2% at the last follow-up. No neurological complications, surgical site infection, screw loosening, internal fixation failure or cage displacement were observed during the follow-up. The fusion rate was 68.8% (11/16) at 6 months post operation. Conclusion: It is safe, feasible and effective to apply cortical screws combined with sacral alar screws in short-segment decompression, fixation and fusion surgery on the lumbosacral region to treat lumbosacral spinal stenosis.
Collapse
|
58
|
Yu S, Sha X, Zhou X, Guo D, Han B, Huang S, Zhu Y. Cyclodextrin-dendrimers nanocomposites functionalized high performance liquid chromatography stationary phase for efficient separation of aromatic compounds. J Chromatogr A 2021; 1662:462730. [PMID: 34896734 DOI: 10.1016/j.chroma.2021.462730] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 11/29/2021] [Accepted: 12/01/2021] [Indexed: 01/03/2023]
Abstract
In this work, novel cyclodextrin-dendrimers nanocomposites functionalized high performance liquid chromatography stationary phases were developed for efficient separation of aromatic compounds. β-cyclodextrin was grafted onto the surface of silica gel matrix with poly (amidoamine) dendrimers as spacers. Scanning electron microscope, fourier transform infrared spectroscopy, element analysis and Brunner-Emmet-Teller measurement proved the successful grafting of cyclodextrin-dendrimers nanocomposites. The obtained stationary phases showed satisfactory separation effects for alkylbenzenes and benzenesulfonic acid substituents in reverse phase liquid chromatography mode. Weak hydrophilic and ion exchange interactions were also confirmed at the same time. Meanwhile, the effects of dendrimers and cyclodextrin on the chromatography performance were discussed. Separation mechanism of the stationary phases were verified by two-dimensional nuclear magnetic resonance technology, and the result implied that the proposed cyclodextrin-dendrimers nanocomposites functionalized stationary phases have significant prospects for separation and determination of more aromatic compounds in future.
Collapse
|
59
|
Zhao XS, Han B, Zhao JX, Tao N, Dong CY. MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 25:6826. [PMID: 34859841 DOI: 10.26355/eurrev_202111_27223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The article "MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1", by X.-S. Zhao, B. Han, J.-X. Zhao, N. Tao, C.-Y. Dong, published in Eur Rev Med Pharmacol Sci 2019; 23 (3): 1030-1037-DOI: 10.26355/eurrev_201902_16990-PMID: 30779069, has been retracted by the authors due to a slight deviation in the data. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/16990.
Collapse
|
60
|
Han B, Tian P, Zhao Y, Yu X, Guo Q, Yu Z, Zhang X, Li Y, Chen L, Shi X, Zhang Y, Wang J. 148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
61
|
Han B, Li K, Wang Q, Cheng Y, Yang L, Li Y. LBA4 The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.219] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
62
|
Rhee C, Kang Y, Han B, Kim YW, Her M, Jeong W, Kim S. Virucidal efficacy of seven active substances in commercial disinfectants used against H9N2 low pathogenic avian influenza virus. J APPL POULTRY RES 2021. [DOI: 10.1016/j.japr.2021.100198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
63
|
Han B, Kovalchuk N, Capaldi D, Simiele E, White J, Purwar A, Yeung T, Maganti S, Mitra A, Voronenko Y, Oderinde O, Shirvani S, Kuduvalli G, Vitzthum L, Chang D, Xing L, Surucu M. First Beam Commissioning Report of a Novel Medical Linear Accelerator Designed for Biologically Guided Radiotherapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
64
|
Han B, Kovalchuk N, Capaldi D, Purwar A, Sun Z, Ye J, Moghadam A, Laurence T, Vitzthum L, Chang D, Xing L, Surucu M. The kVCT System Commissioning of a Novel Medical Linear Accelerator Designed for Biology-Guided Radiotherapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
65
|
Pham D, Breitkreutz D, Simiele E, Capaldi D, Ngo N, Vitzthum L, Gensheimer M, Chin A, Han B, Surucu M, Xing L, Chang D, Kovalchuk N. SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
66
|
Surucu M, Maniyedath A, Narayanan M, Han B, Kovalchuk N, Gensheimer M, Vitzthum L, Iagaru A, Ferri V, Xing L, Shirvani S, Chang D. Comparison of a First-in-Class LINAC-Integrated PET System and a Diagnostic PET/CT Scanner. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1411] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
67
|
Xiong A, Li C, Xu J, Yang X, Nie W, Zhong H, Chu T, Zhang W, Zhong R, Pan F, Shen Y, Lou Y, Zhang B, Han B, Zhang X. FP12.06 Solid Subtype Predicts Early Bone Metastases in Sensitive EGFR-Mutated Lung Adenocarcinoma Patients After Surgery. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
68
|
Wang J, Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu A, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Wang Y, Kang X, Yao S, Keegan P. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.181] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
69
|
Iannaccone S, Phan H, Straub V, Muntoni F, Koenig E, Malhotra J, Han B, Darton E, Mercuri E. DMD - TREATMENT. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
70
|
Iff J, Bungey G, Paine A, Han B, Gordish-Dressman H, Henricson E, McDonald C. DMD - TREATMENT. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
71
|
Qi M, Jiao M, Li X, Hu J, Wang L, Zou Y, Zhao M, Zhang R, Liu H, Mi J, Zhang L, Liu L, Gong Y, Han B. Correction: CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2. Oncogene 2021; 40:6140-6141. [PMID: 34584220 DOI: 10.1038/s41388-021-01995-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
72
|
Han B, Yan B, Gu A, Chu T, Zhang W, Wang H, Zhong H, SHI C, Zhang X. 1238P AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
73
|
Han B, Yang Z, Wang Y, Chen Y, Qian F, Zhang Y, Hu M, Zhang W. 1163P Combined large cell neuroendocrine carcinoma: Clinical characteristics, prognosis and postoperative management. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
74
|
Zhou Q, Kim H, Soo R, Chang GC, Chiu CH, Hayashi H, Kim SW, Teraoka S, Goto Y, Zhou J, Lee V, Han B, Ho J, Kim DW, Lin CC, Lu S, Polli A, Calella A, Mok T, Wu YL. 1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
75
|
Han B, Wang S, Li G, Wang X, Chen Z, Zhao G, Chen Y, Li M, Li Y, Zhang M, Ai S. [Objective sleep characteristics and risk factors for sleep apnea in heart failure patients with different left ventricular ejection fraction]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2021; 41:1415-1419. [PMID: 34658358 DOI: 10.12122/j.issn.1673-4254.2021.09.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the objective sleep characteristics and the independent risk factors for sleep apnea in heart failure (HF) patients with different left ventricular ejection fractions (LVEF). METHODS A total of 107 patients with chronic HF hospitalized in the Department of Cardiology of our hospital from April, 2019 to October, 2020 were included in this study. According to the LVEF measured by echocardiography, the patients were divided into reduced ejection fraction (HFrEF) group (n=35), mid-range ejection fraction (HFmrEF) group (n=21), and preserved ejection fraction (HFpEF) group (n=51). The baseline demographic and clinical characteristics of the patients were recorded. To assess the objective sleep characteristics, whole night polysomnography was scheduled for all the patients. Spearman correlation and multinomial logistic regression analyses were used to explore the factors affecting objective sleep characteristics. RESULTS The patients in HFpEF group had significantly lower proportion of non-rapid eye movement sleep stage 1, apnea hypopnea index (AHI), and central sleep apnea (CSA) than those in HFrEF group (all P < 0.05). The baseline demographic data or sleep structures in HFmrEF group did not differ significantly from those in the other two groups. Spearman correlation analysis revealed significant correlations of the male sex, diuretics use, NT-proBNP, LVEF, and total cholesterol levels with the severity of AHI (all P < 0.05). After adjusting for potential confounders, multiple logistics regression analysis showed that age, drinking, and LVEF levels were independently associated with the severity of AHI (all P < 0.05). CONCLUSION Abnormal objective sleep architectures occur in all HF patients, manifested mainly by sleep apnea. The incidences of sleep apnea and CSA are lower in patients with HFpEF than in those with HFrEF. Age, drinking, and LVEF levels are independent risk factors for the occurrence and severity of sleep apnea.
Collapse
|
76
|
Lackner L, Dusel M, Egorov OA, Han B, Knopf H, Eilenberger F, Schröder S, Watanabe K, Taniguchi T, Tongay S, Anton-Solanas C, Höfling S, Schneider C. Tunable exciton-polaritons emerging from WS 2 monolayer excitons in a photonic lattice at room temperature. Nat Commun 2021; 12:4933. [PMID: 34400620 PMCID: PMC8368091 DOI: 10.1038/s41467-021-24925-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 07/01/2021] [Indexed: 11/30/2022] Open
Abstract
Engineering non-linear hybrid light-matter states in tailored lattices is a central research strategy for the simulation of complex Hamiltonians. Excitons in atomically thin crystals are an ideal active medium for such purposes, since they couple strongly with light and bear the potential to harness giant non-linearities and interactions while presenting a simple sample-processing and room temperature operability. We demonstrate lattice polaritons, based on an open, high-quality optical cavity, with an imprinted photonic lattice strongly coupled to excitons in a WS2 monolayer. We experimentally observe the emergence of the canonical band-structure of particles in a one-dimensional lattice at room temperature, and demonstrate frequency reconfigurability over a spectral window exceeding 85 meV, as well as the systematic variation of the nearest-neighbour coupling, reflected by a tunability in the bandwidth of the p-band polaritons by 7 meV. The technology presented in this work is a critical demonstration towards reconfigurable photonic emulators operated with non-linear photonic fluids, offering a simple experimental implementation and working at ambient conditions.
Collapse
|
77
|
Han B, Li Q, Wang C, Chandrasekaran P, Zhou Y, Qin L, Liu XS, Enomoto-Iwamoto M, Kong D, Iozzo RV, Birk DE, Han L. Differentiated activities of decorin and biglycan in the progression of post-traumatic osteoarthritis. Osteoarthritis Cartilage 2021; 29:1181-1192. [PMID: 33915295 PMCID: PMC8319061 DOI: 10.1016/j.joca.2021.03.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 03/01/2021] [Accepted: 03/19/2021] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To delineate the activities of decorin and biglycan in the progression of post-traumatic osteoarthritis (PTOA). DESIGN Three-month-old inducible biglycan (BgniKO) and decorin/biglycan compound (Dcn/BgniKO) knockout mice were subjected to the destabilization of the medial meniscus (DMM) surgery to induce PTOA. The OA phenotype was evaluated by assessing joint structure and sulfated glycosaminoglycan (sGAG) staining via histology, surface collagen fibril nanostructure and calcium content via scanning electron microscopy, tissue modulus via atomic force microscopy-nanoindentation, as well as subchondral bone structure and meniscus ossification via micro-computed tomography. Outcomes were compared with previous findings in the inducible decorin (DcniKO) knockout mice. RESULTS In the DMM model, BgniKO mice developed similar degree of OA as the control (0.44 [-0.18 1.05] difference in modified Mankin score), different from the more severe OA phenotype observed in DcniKO mice (1.38 [0.91 1.85] difference). Dcn/BgniKO mice exhibited similar histological OA phenotype as DcniKO mice (1.51 [0.97 2.04] difference vs control), including aggravated loss of sGAGs, salient surface fibrillation and formation of osteophyte. Meanwhile, Dcn/BgniKO mice showed further cartilage thinning than DcniKO mice, resulting in the exposure of underlying calcified tissues and aberrantly high surface modulus. BgniKO and Dcn/BgniKO mice developed altered subchondral trabecular bone structure in both Sham and DMM groups, while DcniKO and control mice did not. CONCLUSION In PTOA, decorin plays a more crucial role than biglycan in regulating cartilage degeneration, while biglycan is more important in regulating subchondral bone structure. The two have distinct activities and modest synergy in the pathogenesis of PTOA.
Collapse
|
78
|
Yao Y, Zhang C, Xiong Y, Han B, Gao X, Wang S. [miR-let-7c-5p inhibits invasion and migration of bladder cancer cells by targeting HMGA2]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2021; 41:1022-1029. [PMID: 34308851 DOI: 10.12122/j.issn.1673-4254.2021.07.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate whether miR-let-7c-5p inhibits invasion and migration of bladder cancer cells by regulating HMGA2. METHODS We used bioinformatics methods to determine the key genes of miR-let-7c-5p. RT-qPCR and Western blotting were used to detect the expressions of miR-let-7c-5p mRNA and HMGA2 protein in bladder cancer and adjacent tissues. With human normal bladder SV-HUC-1 cells as the control, we detected the expression levels of miR-let-7c-5p mRNA and HMGA2 protein in bladder cancer cell lines T24, UM-UC-3 and 5637 with RT-qPCR and Western blotting. We observed the effects of miR-let-7c-5p upregulation (by transfection with a miR-let-7c-5p mimic), miR-let-7c-5p downregulation (using a miR-let-7c-5p inhibitor), and knockdown of both HMGA2 and miR-let-7c-5p on invasion, migration and expressions of epithelial-mesenchymal transition (EMT)-related proteins (E-cadherin, N-cadherin, vimentin, and Snail) in UM-UC-3 cells. Dual luciferase assay, RT-qPCR and Western blotting were used to verify the targeting relationship between miR-let-7c-5p and HMGA2. RESULTS HMGA2 was identified as one of the target genes of miR-let-7c-5p. Compared with the adjacent tissues, bladder cancer tissues showed a significantly decreased expression of miR-let-7c-5p and an increased expression of HMGA2 protein (P < 0.05). In UM-UC-3 cells, the expression of miR-let-7c-5p was significantly reduced and that of HMGA2 was significantly increased as compared with those in SV-HUC-1 cells (P=0.001). Up-regulating miR-let-7c-5p expression significantly lowered the invasion and migration abilities of UM-UC-3 cells, and down-regulating miR-let-7c-5p expression obviously promoted the invasion and migration of UM-UC-3 cells (P < 0.05). Knockdown of both miR-let-7c-5p and HMGA2 expression significantly lowered the invasion and migration (P < 0.05) and inhibited the expressions of EMT-related proteins of UM-UC-3 cells (P < 0.05). CONCLUSION miR-let-7c-5p inhibits EMT of bladder cancer UM-UC-3 cells by targeting HMGA2, thereby inhibiting the cell invasion and migration.
Collapse
|
79
|
Han B, Li S, Li Z, Huang G, Tian J, Cao X. Asymmetric transmission for dual-circularly and linearly polarized waves based on a chiral metasurface. OPTICS EXPRESS 2021; 29:19643-19654. [PMID: 34266071 DOI: 10.1364/oe.425787] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 05/30/2021] [Indexed: 06/13/2023]
Abstract
We propose a chiral metasurface (CMS) that exhibits asymmetric transmission (AT) of double circularly and linearly polarized waves at the same frequency band. In order to realize the manipulation of electromagnetic (EM) waves in the whole space, the unit cell of CMS consists of three layers of dielectric substrate and four layers of metal patches. The Z-shaped chiral micro-structure and a grating-like micro-structure are proposed and designed to achieve AT. The simulated results show that the x-polarized wave that is incident along one direction can be transmitted into the right-hand circularly polarized (RHCP) wave and the left-hand circularly polarized (LHCP) wave that is incident along the opposite direction can be reflected as the LHCP wave in the frequency band of 4.69GHz-5.84 GHz. The maximum chirality response can be reflected by AT and circular dichroism (CD) and they can reach up to 0.38 and 0.75, respectively. In addition, we also produced the sample of CMS, and the experimental results are in good agreement with the simulated results.
Collapse
|
80
|
Tian J, Cao X, Gao J, Li S, Yang H, ZHang Z, Han B. Reconfigurable time-frequency division multiplexing metasurface: giving a helping hand to high signal-to-noise ratio and high data holographic imaging. OPTICS EXPRESS 2021; 29:20286-20298. [PMID: 34266121 DOI: 10.1364/oe.430176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 06/05/2021] [Indexed: 06/13/2023]
Abstract
A holographic imaging system based on reconfigurable time-frequency division multiplexing metasurface (RTFDMM) has been designed, in an attempt to address the problems of insufficient flexibility, low signal-to-noise ratio (SNR), and low data of traditional metasurface imaging devices. The modified Gerchberg-Saxton (MGS) algorithm in the front end of this system has been proposed to calculate the phase distribution required by the diffraction metasurface at the back end. The 1-bit low loss reconfigurable metasurface has been desiged in X-band. To obtain the best imaging results, the appropriate ranges of imazging distance, pixel size and resolution ratio are given by adjusting the phase distribution of metasurface. Based on the MGS algorithm and the 1-bit metasurface, the high-quality imaging system has been successfully established through the time-frequency division multiplexing (TFDM) technology. The high SNR imaging can be generated with the expansion of the time domain, while the high data imaging can be yielded with the quantization of the frequency domain. The proof-of-concept has demonstrated that the high data, high SNR, and high flexibility of the RTFDMM are critical technologies for the advancement of detection imaging equipment. Therefore, there are great possibilities for RTFDMM holographic imaging system to be applied in the intelligent detection platform in the future.
Collapse
|
81
|
Cho S, Lee D, Han B, Lee J, Hong J, Chung J, Lee D, Na J. 463 Automated atopic dermatitis severity assessment based on convolutional neural networks. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
82
|
Hu M, Lu J, Han B. 20P Synergistic inhibition of growth of KRAS-driven NSCLC by MEK inhibitor in combination with a novel multi-target tyrosine kinase inhibitor anlotinib via IGFBP-mediated signaling. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01862-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
83
|
Ling X, Xu J, Zhong R, Zhong H, Han B. 101MO Efficacy and safety of DCVAC/LuCa with chemotherapy for patients with stage IV NSCLC: A prospective, open-label, single-arm, phase II study. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01943-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
84
|
Yu L, Xu J, Qiao R, Zhong H, Han B, Zhong R. 59P Patterns of recurrence and survival after complete resection of pathological stage N2 small cell lung cancer. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01901-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
85
|
Cui L, Wang LL, Li XJ, Wang LG, Li MZ, Han B. [Hypertrophic cardiomyopathy complicated with apical left ventricular aneurysm and ventricular tachycardia: a case report]. ZHONGHUA XIN XUE GUAN BING ZA ZHI 2021; 49:276-277. [PMID: 33706463 DOI: 10.3760/cma.j.cn112148-20200413-00307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
|
86
|
Chu T, Zhang W, Zhang B, Zhong R, Shi C, Zhang X, Qian J, Han B. P76.10 Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
87
|
Han B, Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Chang Q, Zhang X, Dong Y, Teng J, Gao Z, Qiang H, Nie W, Zhao Y, Han Y, Chen Y. OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
88
|
Han B, Hu M, Zhong R. P14.29 Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
89
|
Han B, Qian F, Zhang Y, Zhang B, Wang S. P46.04 Identify Lung Adenocarcinoma among Pulmonary Micro-nodules through Blood Gene Expression Profiles. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
90
|
Han B, Qian F, Zhang Y, Zhang B, Wang S. P46.05 A Blood Six-Gene Test for Early-Stage Lung Adenocarcinoma Screening in Asympomatic Population. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
91
|
Han B, Zhang W, Zhang B, Chen Y, Zhang Y, Lou Y, Dong Y, Qian F, Zhou W, Yang Z. P48.09 Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
92
|
Han B, Zhang W, Shi C, Chu T, Zhong H, Zhang Y, Lou Y, Dong Y, Qian F, Zhou W, Chen Y, Yang Z. P15.07 Safety and Efficacy Profile of TQB-2450 Alone/with Anlotinib in Previously-Treated Advanced NSCLC: A Phase IB Single-Arm Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.544] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
93
|
Han B, Zhang B, Shi C, Gao Z, Zhong H, Xiong L, Gu A, Wang W, Chu T, Zhang W, Wang H, Zhang X, Zhong R. P76.59 Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
94
|
Han B, Chen J, Xie Q, Yao W, Shi H, Zhao Y, Song W, Jin X, Wang Z, Li B, Xia Y, Jiao S. P80.01 A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
95
|
Nie W, Han B. OA07.03 Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
96
|
Chen WS, Zhang ML, Han B. [Comparison of genetic mutations in myelodysplastic syndrome and acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2021; 42:171-176. [PMID: 33858051 PMCID: PMC8071666 DOI: 10.3760/cma.j.issn.0253-2727.2021.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Indexed: 11/23/2022]
|
97
|
Hu J, Han B. [Interpretation and research advances on molecular biomarkers in prostate cancer from 2020 International Society of Urological Pathology consultation conference report]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2021; 50:172-176. [PMID: 33535320 DOI: 10.3760/cma.j.cn112151-20200922-00732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
98
|
Wang L, Zhang Y, Wang W, Zhang L, Yang C, Zhuang JL, Han B, Zhou DB, Chen M. [Clinical analysis in five patients with acute leukemia and HIV infection]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2021; 41:517-520. [PMID: 32654469 PMCID: PMC7378282 DOI: 10.3760/cma.j.issn.0253-2727.2020.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
99
|
Chen FF, Guo ZW, Zhang LN, Yang C, Chen M, Ye F, Han B. [The change of quality of life in 52 patients with non-severe aplastic anemia after cyclosporine A therapy]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2021; 41:806-810. [PMID: 33190436 PMCID: PMC7656084 DOI: 10.3760/cma.j.issn.0253-2727.2020.10.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
目的 研究非重型再生障碍性贫血(NSAA)患者接受环孢素A(CsA)治疗前后生活质量的变化,并分析生活质量改善的影响因素。 方法 收集2014年1月至2016年1月在北京协和医院门诊初次治疗、仅使用CsA的NSAA患者,在治疗前和治疗2年后分别填写SF-36量表,与正常中国人模型(常模)比较;并调查评估患者的年龄、性别、文化程度、家庭年收入、付费方式、依从性、治疗前一般健康状况及治疗2年后的疗效,分析其与生活质量改善的关系。 结果 共52例患者符合入组条件,其中男性27例(51.9%),女性25例(48.1%),中位年龄48(21~85)岁。CsA治疗2年,完全治疗反应(CR)15例(28.8%),部分治疗反应(PR)25例(48.1%),无治疗反应(NR)12例(23.1%),治疗总有效率(CR+PR)76.9%。患者治疗前SF-36量表躯体和心理健康得分差于常模(P值均<0.05)。治疗后,躯体方面及总体生活质量虽仍然低于常模(P值均<0.05),但心理健康与常模比较差异无统计学意义(P值均>0.05),精力(VT)、精神健康(MH)得分高于常模[VT:(58.8±20.1)分对(52.3±20.9)分,P=0.023;MH:(65.9±17.6)分对(59.7±22.9)分,P=0.014]。不同社会背景与生活质量改善均无显著相关性。起病时体能状况评分(ECOG评分)较低者生活质量改善更大。CsA治疗有效者生活质量均得到显著改善。 结论 NSAA患者生活质量低于常人,CsA治疗可以改善患者的生活质量,尤其是心理健康情况。不同社会背景的患者均可从治疗中获益,而起病较重者获益更大。
Collapse
|
100
|
Han B, Isborn CM, Shi L. Determining Partial Atomic Charges for Liquid Water: Assessing Electronic Structure and Charge Models. J Chem Theory Comput 2021; 17:889-901. [PMID: 33405925 DOI: 10.1021/acs.jctc.0c01102] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Partial atomic charges provide an intuitive and efficient way to describe the charge distribution and the resulting intermolecular electrostatic interactions in liquid water. Many charge models exist and it is unclear which model provides the best assignment of partial atomic charges in response to the local molecular environment. In this work, we systematically scrutinize various electronic structure methods and charge models (Mulliken, natural population analysis, CHelpG, RESP, Hirshfeld, Iterative Hirshfeld, and Bader) by evaluating their performance in predicting the dipole moments of isolated water, water clusters, and liquid water as well as charge transfer in the water dimer and liquid water. Although none of the seven charge models is capable of fully capturing the dipole moment increase from isolated water (1.85 D) to liquid water (about 2.9 D), the Iterative Hirshfeld method performs best for liquid water, reproducing its experimental average molecular dipole moment, yielding a reasonable amount of intermolecular charge transfer, and showing modest sensitivity to the local water environment. The performance of the charge model is dependent on the choice of the density functional and the quantum treatment of the environment. The computed molecular dipole moment of water generally increases with the percentage of the exact Hartree-Fock exchange in the functional, whereas the amount of charge transfer between molecules decreases. For liquid water, including two full solvation shells of surrounding water molecules (within about 5.5 Å of the central water) in the quantum chemical calculation converges the charges of the central water molecule. Our final pragmatic quantum chemical charge-assigning protocol for liquid water is the Iterative Hirshfeld method with M06-HF/aug-cc-pVDZ and a quantum region cutoff radius of 5.5 Å.
Collapse
|